Acadia PharmaceuticalsACAD
ACAD
About: Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Employees: 620
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
151% more call options, than puts
Call options by funds: $16M | Put options by funds: $6.39M
9% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 81
4% less funds holding
Funds holding: 265 [Q2] → 255 (-10) [Q3]
5.75% less ownership
Funds ownership: 99.02% [Q2] → 93.27% (-5.75%) [Q3]
10% less capital invested
Capital invested by funds: $2.66B [Q2] → $2.38B (-$278M) [Q3]
22% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 46
40% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 3 (-2) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
58%
upside
Avg. target
$28
61%
upside
High target
$28
64%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target | 64%upside $28 | Buy Reiterated | 7 Nov 2024 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 58%upside $27 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 8 articles about ACAD published over the past 30 days
Neutral
Business Wire
5 days ago
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadia's presentation will be accessible on the company's website, Acadia.com, under the investors section and an archi.
Neutral
Business Wire
1 week ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units (“RSUs”) to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.
Neutral
Business Wire
1 week ago
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license agreement between the companies. Acadia plans to invest proceeds from the sale of the PRV to.
Neutral
Business Wire
2 weeks ago
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. “Tom is.
Positive
Zacks Investment Research
3 weeks ago
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Seeking Alpha
3 weeks ago
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis.
Positive
Zacks Investment Research
4 weeks ago
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Neutral
Business Wire
4 weeks ago
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the bo.
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore HealthCONx Conference Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, und.
Neutral
Business Wire
1 month ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employ.
Charts implemented using Lightweight Charts™